Yes, Ogsiveo Treats Desmoid Tumors
Ogsiveo (nirogacestat) is FDA-approved for adult patients with progressing desmoid tumors not amenable to surgery.[1] The agency granted accelerated approval in November 2023 based on the DeFi Phase 3 trial, where 41% of patients on Ogsiveo had a confirmed partial response versus 8% on placebo, with tumor shrinkage or halted growth in most cases.[2]
How Ogsiveo Works Against Desmoid Tumors
Desmoid tumors are rare, aggressive soft-tissue sarcomas driven by gamma-secretase, an enzyme that activates beta-catenin signaling. Ogsiveo inhibits gamma-secretase, blocking this pathway to slow tumor growth. In trials, median progression-free survival reached 25.7 months versus 13.8 months on placebo.[1][2]
Who Qualifies for Ogsiveo Treatment
It's indicated only for progressing cases where surgery risks harm, such as near vital organs. Patients must have confirmed disease progression via imaging. It's not approved for children or non-progressing tumors.[1]
Common Side Effects Patients Report
Fatigue (72%), diarrhea (72%), nausea (48%), ovarian dysfunction or amenorrhea (75% in females of childbearing age), and hair loss occur frequently. Serious risks include ovarian failure, liver enzyme elevation, and fetal harm—pregnancy testing and contraception are required.[1]
When Did Approval Happen and What's Next
Accelerated approval came November 27, 2023, from SpringWorks Therapeutics. Full approval depends on confirmatory trials verifying clinical benefit. No generic or biosimilar exists yet.[1]
Alternatives if Ogsiveo Isn't Suitable
Options include watchful waiting, surgery (if feasible), radiation, or off-label sorafenib/doxorubicin. No other FDA-approved systemic therapies exist specifically for desmoid tumors.[2]
Sources
[1]: FDA Label for Ogsiveo
[2]: NEJM DeFi Trial Results